A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy

2021 ◽  
Vol 154 ◽  
pp. 288-295
Author(s):  
In Sil Choi ◽  
Ki Hwan Kim ◽  
Ju Hyun Lee ◽  
Koung Jin Suh ◽  
Ji-Won Kim ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
First Line ◽  
Tract Cancer

Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15150-e15150
Author(s):  
Eun-Kee Song ◽  
Hye-Suk Han ◽  
Ki Hyeong Lee ◽  
Kyu Taek Lee ◽  
Sang Byung Bae ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Tract Cancer ◽  
Multicenter Phase

A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer

2018 ◽  
Vol 41 (7) ◽  
pp. 649-655 ◽  
Author(s):  
Renuka V. Iyer ◽  
Venkata K. Pokuri ◽  
Adrienne Groman ◽  
Wen W. Ma ◽  
Usha Malhotra ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Tract Cancer ◽  
Multicenter Phase

scholarly journals Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Qiyi Zhang ◽  
Xingyu Liu ◽  
Shumei Wei ◽  
Lufei Zhang ◽  
Yang Tian ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Objective Response ◽  
Pathologic Response ◽  
Line Treatment ◽  
First Line ◽  
Tract Cancer ◽  
First Line Treatment

ObjectiveWe investigated lenvatinib plus programmed cell death-1 (PD-1) inhibitors as a first-line treatment for initially unresectable biliary tract cancer (BTC).MethodsIn this Phase II study, adults with initially unresectable BTC received lenvatinib (body weight ≥60 kg, 12 mg; <60 kg, 8 mg) daily and PD-1 inhibitors (pembrolizumab/tislelizumab/sintilimab/camrelizumab 200 mg or toripalimab 240 mg) every 3 weeks. Primary endpoints were objective response rate (ORR) and safety. Secondary endpoints included surgical conversion rate, disease control rate (DCR), event-free survival (EFS), overall survival (OS) and tumor biomarkers.ResultsAmong 38 enrolled patients, the ORR was 42.1% and the DCR was 76.3%. Thirteen (34.2%) patients achieved downstaging and underwent surgery, six of whom (46.2%) achieved a major pathologic response (n=2) or partial pathologic response (n=4) in the primary tumor. In total, 84.2% of patients experienced ≥1 treatment-related adverse event (TRAE), 34.2% experienced a Grade ≥3 TRAE and no treatment-related deaths occurred. After a median follow-up of 13.7 months the median EFS was 8.0 months (95% CI: 4.6–11.4) and the median OS was 17.7 months (95% CI: not estimable).ConclusionsLenvatinib plus PD-1 inhibitors showed promising anti-tumor efficacy in patients with initially unresectable BTC and was generally well tolerated.Clinical Trial Registrationwww.chictr.org.cn, ChiCTR2100044476.

A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer

2009 ◽  
Vol 64 (2) ◽  
pp. 371-377 ◽  
Author(s):  
Hyun Jung Kim ◽  
Nam Su Lee ◽  
Sang-Cheol Lee ◽  
Sang Byung Bae ◽  
Chan Kyu Kim ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
First Line ◽  
Tract Cancer ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document